Financial Performance - Cerus reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.07 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $45.08 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 6.07%, compared to year-ago revenues of $38.85 million [2] - Over the last four quarters, Cerus has exceeded consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Cerus shares have increased by approximately 4.6% since the beginning of the year, while the S&P 500 has gained 15.8% [3] - The company's earnings outlook will be crucial for future stock movements, with current consensus EPS estimates at -$0.02 on $43.7 million in revenues for the coming quarter and -$0.10 on $174 million in revenues for the current fiscal year [4][7] Industry Context - The Medical - Products industry, to which Cerus belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Cerus may also be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 68-0262011 (State or other jurisdiction ...

Exhibit 99.1 Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million CONCORD, CA, August 1, 2024 - Cerus Corporation (Nasdaq: CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months end ...

Financial Data and Key Metrics Changes - The company reported product revenue of $38.4 million for Q1 2024, representing a year-over-year growth of 24% [29] - Operating expenses for Q1 2024 totaled $34.3 million, a decrease of 12% from $38.9 million in the prior year [32] - The net loss attributable to the company narrowed by 38% to $9.7 million or $0.05 per diluted share compared to $15.6 million or $0.09 per diluted share for the prior year [55] Business Line Data and Key Metrics Changes - The U.S. INTERCEPT Fibrinogen Complex (IFC) generated revenue of $1.9 million in Q1, driven by national sales agreements with large U.S. blood center partners [53] - North American platelet sales were the major contributor to product revenue growth, exceeding prior year levels by more than 40% [29] - EMEA product revenues decreased by 9% year-over-year, primarily due to delays in order fulfillment [30] Market Data and Key Metrics Changes - The Canadian market is nearing full implementation of INTERCEPT platelets, with nearly 100% adoption across Canadian Blood Services [52] - The Gulf region is identified as a targeted growth area due to increased healthcare investments and a focus on blood safety [49] - The company expects growth in EMEA and the U.S. following the resolution of timing issues related to order patterns [64] Company Strategy and Development Direction - The company is committed to achieving adjusted EBITDA breakeven for the full year 2024 [23] - The growth strategy includes expanding the INTERCEPT platelet business in North America and Europe, as well as increasing uptake of IFC in the U.S. [34] - The company is actively working to increase manufacturing capacity to meet anticipated demand [91] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for continued growth in the top line and stable gross margins [8] - The company is increasingly confident in its growth expectations for 2024, reiterating product revenue guidance of $172 million to $175 million [34] - Management noted that the extended shelf life of products is expected to relieve supply chain pressure and mitigate risks of product obsolescence [25] Other Important Information - The company generated positive operating cash flows of $2 million for Q1 2024, compared to cash used from operations of $8.5 million in the prior year [81] - The company is awaiting feedback from the Netherlands competent authority regarding regulatory questions [3] Q&A Session Summary Question: What is the status of reimbursement for IFC? - Management confirmed that reimbursement for IFC is linked to the NTAP and is optimistic about its evolution [93] Question: Can you provide more details on the international business weakness? - Management clarified that the decline in EMEA was primarily due to timing issues rather than fundamental weaknesses, expecting a rebound [64] Question: What is the update on regulatory progress in China? - The company is awaiting additional questions from the NPA and expects to provide clarity on timing for approval in the second quarter [65] Question: Are expectations for guidance trending towards the higher end? - Management indicated increased confidence in guidance but emphasized the need to see Q2 results before making definitive statements [67][68] Question: What are the trends in IFC growth with blood centers? - Management noted a material increase in orders from blood centers directly distributing IFC, validating the strength of that channel [90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 68-0262011 (State or other jurisdiction ...

First Quarter Product Revenue Increased 24% from Prior Year Quarter Three Months Ended March 31, 2024 2023 Product Revenue $38,365 $30,974 Government Contract Revenue 5,030 7,502 Total Revenue $43,395 $38,476 • The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in this range is full-year 2024 guidance for INTERCEPT Fibrinogen Complex, which is expected to be between $8 million to $10 million. • The Company expects to report GAAP net ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensitive transfusio ...

Financial Data and Key Metrics Changes - In Q4 2023, product gross profit was $26 million, a 6% increase from $24.5 million in the prior year period, with product gross margins at 55.5%, stable compared to the previous year and slightly up from Q3 [3][14][21] - The net loss attributable to Cerus for Q4 2023 was $1.3 million, significantly improved from $13.6 million in the same period last year [63] - Non-GAAP adjusted EBITDA was positive for the first time, reaching almost $5 million, an improvement of over $8 million compared to Q4 2022 [21][60] Business Line Data and Key Metrics Changes - The U.S. product revenues in Q4 2023 exceeded prior year levels, increasing sequentially by 22% from Q3 [18][20] - The INTERCEPT Fibrinogen Complex (IFC) is expected to generate annual revenue of $8 million to $10 million in 2024, marking a significant growth opportunity [4][68] - The platelet franchise showed strong growth globally, with Canadian Blood Services implementing INTERCEPT for whole blood derived platelets, achieving over 85% of platelet units issued to hospitals being INTERCEPT treated [16][59] Market Data and Key Metrics Changes - In EMEA, Q4 product revenues were up 3% year-over-year and around 2% compared to Q3 2023, with foreign exchange rates providing a benefit of approximately 430 basis points [18] - The company anticipates continued growth in the U.S. platelet franchise and IFC business, with significant opportunities in international markets such as Germany and the Middle East [72][74] Company Strategy and Development Direction - The company is focused on international expansion of INTERCEPT platelets and growth of IFC in the U.S., with a commitment to maintaining pricing discipline amid inflation [2][74] - The strategic emphasis is on deepening relationships with existing customers and activating new accounts, particularly in the IFC business [70][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2024, expecting double-digit growth in product revenues and improved bottom-line results [14][41] - The company is optimistic about the ReCePI trial results and anticipates providing updates on its progress throughout the year [43][91] Other Important Information - Operating expenses in Q4 2023 totaled $31.6 million, a 24% decline from $41.8 million in the prior year, reflecting the impact of a restructuring initiative [37][38] - The cash position at the end of Q4 2023 was $65.9 million, with cash used from operations at $15.2 million, compared to $1.8 million in the prior year [40][65] Q&A Session Summary Question: What is the expected revenue for IFC in 2024 and its potential market size? - The company expects IFC revenue to be in the range of $8 million to $10 million for 2024, with a total addressable market estimated between $200 million to $300 million [68][44] Question: Can you provide insights on international growth, particularly in Germany and China? - The company anticipates continued progress in Germany and sees growth opportunities in the Middle East, while the regulatory process in China is ongoing with no indication of needing a clinical trial [72][73] Question: What are the expectations for positive EBITDA in 2024? - Management indicated that positive EBITDA is a reasonable assumption for the entire year, with expectations for stability and potential improvement from Q4 levels [70][64]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 68-0262011 (State or other jurisdiction of incorporation ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the ...